Changes in high-rank­ing ex­ecs poised to deep­en at Karyopharm; Till­man Gern­gross-chaired biotech pro­motes new med­ical chief to CEO

→ Round and round the ex­ec­u­tive carousel turns at Karyopharm as Resh­ma Rang­wala re­places Jatin Shah as CMO, a month re­moved from the FDA pulling the rug out from un­der se­linex­or’s chances in en­dome­tri­al can­cer by call­ing for a new tri­al first. The rem­nants of the old guard at Karyopharm con­tin­ue to peel off, with co-founder and CSO Sharon Shacham now step­ping down along­side se­nior clin­i­cal ad­vi­sor and ex-CEO Michael Kauff­man start­ing May 31.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER